PerpEquities

Laporan laba rugi Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ · Healthcare · Biotechnology · Karyawan: 975 · CEO: Frederick G. Vogt

Harga
$8,48 -11,30%
Kapitalisasi pasar
$3,84 M
Nilai perusahaan
$3,78 M
Laporan terakhir
Q2 '26 diajukan 2026-08-06
Laporan berikutnya
2026-11-05 Estimasi EPS: -$0,08

Iovance Biotherapeutics, Inc. (IOVA) untuk Q2 '26: pendapatan $99,3 jt (+65,7% yoy), laba operasional -$51,9 jt (-52,3% dari pendapatan), laba bersih -$47,3 jt. Dalam empat kuartal terakhir pendapatan mencapai $325 jt.

Laporan laba rugi

Laporan laba rugiTrenQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Pendapatan$469 rb$482 rb$715 rb$31,1 jt$58,6 jt$73,7 jt$49,3 jt$60 jt$67,5 jt$86,8 jt$71,4 jt$99,3 jt
Beban pokok pendapatan$4,34 jt$4,37 jt$7,26 jt$31,4 jt$39,8 jt$45,5 jt$42,7 jt$48,9 jt$38,5 jt$43,1 jt$42,5 jt$43,6 jt
Laba kotor-$3,87 jt-$3,88 jt-$6,55 jt-$262 rb$18,7 jt$28,2 jt$6,61 jt$11,1 jt$29 jt$43,7 jt$28,9 jt$55,7 jt
Riset & pengembangan$87,5 jt$87,5 jt$79,8 jt$62,1 jt$68,2 jt$72,2 jt$76 jt$77,9 jt$75,2 jt$71,2 jt$62,5 jt$58,9 jt
Penjualan & pemasaran$0$0$17,9 jt$0$0$0$0$0$0$0$0$0
Umum & administrasi$0$0$8,26 jt$0$39,6 jt$0$0$0$0$0$0$0
Beban operasional lainnya$0$0$5,27 jt$5,38 jt-$1 rb$0$8,07 jt$9,35 jt$9,01 jt$9,52 jt$8,54 jt$9,5 jt
Beban operasional$114 jt$117 jt$111 jt$102 jt$108 jt$115 jt$128 jt$125 jt$119 jt$117 jt$110 jt$108 jt
Laba operasional-$118 jt-$121 jt-$118 jt-$102 jt-$89,1 jt-$86,6 jt-$121 jt-$114 jt-$89,8 jt-$73,5 jt-$81 jt-$51,9 jt
Pendapatan bunga$3,36 jt$3,12 jt$3,34 jt$3,36 jt$4,01 jt$9,58 jt$3,22 jt$4,1 jt$1,24 jt$1,74 jt$1,33 jt$3,22 jt
Pendapatan non-operasional lainnya (keuntungan investasi, kurs ...)-$3,36 jt-$3,12 jt-$3,34 jt-$3,36 jt$1 rb-$9,58 jt$0$0$0$0$0$0
Total pendapatan non-operasional$3,36 jt$3,12 jt$3,34 jt$3,36 jt$4,01 jt$9,58 jt$3,22 jt$4,1 jt-$3,9 jt$1,74 jt$1,33 jt$3,22 jt
Laba sebelum pajak-$115 jt-$118 jt-$114 jt-$98,6 jt-$85,1 jt-$77 jt-$118 jt-$110 jt-$93,7 jt-$71,7 jt-$79,7 jt-$48,7 jt
Pajak penghasilan-$1,24 jt-$1,76 jt-$1,41 jt-$1,46 jt-$1,52 jt$1,56 jt-$1,84 jt$1,99 jt-$2,41 jt$184 rb-$665 rb-$1,37 jt
Laba bersih-$114 jt-$116 jt-$113 jt-$97,1 jt-$83,5 jt-$78,6 jt-$116 jt-$112 jt-$91,3 jt-$71,9 jt-$79 jt-$47,3 jt
EPS (dasar)-$0,46-$0,45-$0,42-$0,34-$0,28-$0,26-$0,36-$0,33-$0,25-$0,18-$0,19-$0,11
EPS (dilusian)-$0,46-$0,45-$0,42-$0,34-$0,28-$0,26-$0,36-$0,33-$0,25-$0,18-$0,19-$0,11
Saham (dasar, rata-rata tertimbang)246 jt256 jt266 jt285 jt303 jt305 jt323 jt335 jt364 jt407 jt419 jt450 jt
Saham (dilusian, rata-rata tertimbang)246 jt256 jt266 jt285 jt303 jt305 jt323 jt335 jt364 jt407 jt419 jt450 jt
Depresiasi & amortisasi$9,88 jt$9,71 jt$9,91 jt$10,9 jt$11,1 jt$11,7 jt$10,9 jt$12,2 jt$11,5 jt$12,6 jt$10,4 jt$10,4 jt
EBITDA-$105 jt-$108 jt-$104 jt-$87,7 jt-$77,9 jt-$65,3 jt-$110 jt-$102 jt-$78,2 jt-$60,8 jt-$70,6 jt-$41,5 jt

Distandardisasi dari laporan perusahaan; arus keluar dan biaya mempertahankan tanda yang dilaporkan penyedia. Arahkan kursor ke periode untuk melihat tanggal berakhirnya. Jumlah dalam USD.

Pendapatan, laba operasional, dan pertumbuhan

kuartalan

Margin

kuartalan

Biaya sebagai % pendapatan

kuartalan

Laporan lainnya

Sumber

Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30

Data per 2026-11-02